Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta‐analysis

2022 ◽  
Author(s):  
Fabio Mangiacapra ◽  
Luca Paolucci ◽  
Michele M. Viscusi ◽  
Roberto Mangiacapra ◽  
Pietro M. Ferraro ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Percutaneous Coronary Intervention ◽  
Kidney Disease ◽  
Platelet Reactivity ◽  
Meta Analysis ◽  
Coronary Intervention ◽  
Clinical Impact ◽  
High Platelet Reactivity ◽  
Percutaneous Coronary

scholarly journals 719 Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: an updated systematic review and meta-analysis

2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Fabio Mangiacapra ◽  
Luca Paolucci ◽  
Michele Mattia Viscusi ◽  
Roberto Mangiacapra ◽  
Pietro Manuel Ferraro ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Percutaneous Coronary Intervention ◽  
Kidney Disease ◽  
Platelet Reactivity ◽  
Meta Analysis ◽  
Coronary Intervention ◽  
Cochrane Library ◽  
Major Adverse Cardiovascular Events ◽  
High Platelet Reactivity ◽  
Percutaneous Coronary

Abstract Aims High platelet reactivity (HPR) on clopidogrel and chronic kidney disease (CKD) are recognized as potent risk factors for adverse outcomes in patients suffering coronary artery disease (CAD) and undergoing percutaneous coronary intervention (PCI). However, conclusive evidence regarding their reciprocal interaction and the consequent impact on clinical events is still lacking. We performed a meta-analysis with the aim to evaluate the prevalence of HPR in patients with and without CKD and the incidence of major adverse cardiovascular events (MACE) according to the renal and platelet function status in current literature (co-primary endpoints). Secondary endpoints were myocardial infarction (MI), all cause death and definite/probable stent thrombosis (ST). Methods and results We searched on PubMed, EMBASE, and Cochrane Library studies investigating CKD and HPR on clopidogrel in patients suffering CAD who underwent PCI and their related outcomes. Overall, 13 studies including 22.464 patients were selected. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using random-effects model with the Mantel–Haenszel method. Patients with CKD presented significantly higher odds of HPR compared with those without CKD [OR: 1.51 (95% CI: 1.29–1.76)]. In patients without CKD, HPR was associated with increased odds of MACE [OR: 1.31 (95% CI: 1.01–1.72)], MI [OR: 1.48 (95% CI: 1.17–1.86)] and definite/probable ST [OR: 2.45 (95% CI: 1.08–5.60)]. In patients with CKD, HPR was associated with higher odds of both MACE [OR: 1.61 (95% CI: 1.14–2.27)] and MI [OR: 1.69 (95% CI: 1.11–2.59)], compared to those without HPR. Conclusions Our analysis shows that HPR on clopidogrel is more frequent in patients with CKD treated with PCI. Patients with HPR are exposed to a high risk of MACE after PCI, regardless of the renal function status.

Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis

2010 ◽  
Vol 160 (3) ◽  
pp. 543-551 ◽  
Author(s):  
Dániel Aradi ◽  
András Komócsi ◽  
András Vorobcsuk ◽  
Orsolya Rideg ◽  
Margit Tőkés-Füzesi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Percutaneous Coronary Intervention ◽  
Platelet Reactivity ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Coronary Intervention ◽  
Percutaneous Coronary

Platelet reactivity in patients with chronic kidney disease undergoing percutaneous coronary intervention

Platelets ◽  
2018 ◽  
Vol 30 (7) ◽  
pp. 901-907 ◽  
Author(s):  
Pei Zhu ◽  
Xiao-Fang Tang ◽  
Jing-Jing Xu ◽  
Ying Song ◽  
Ru Liu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Percutaneous Coronary Intervention ◽  
Kidney Disease ◽  
Platelet Reactivity ◽  
Coronary Intervention ◽  
Percutaneous Coronary
Sign in / Sign up

Export Citation Format

Share Document